三生国健公告，核心技术人员翁志兵因个人原因申请辞去在全资子公司担任的所有职务，离职后不再担 任公司任何职务。截至公告日，翁志兵持有公司股份30股。其在职期间负责的工作已交接，离职不影响 公司专利等知识产权的完整性，不会对生产经营、研发实力、核心竞争力和产品创新产生不利影响。 ...

证券代码： 688336 证券简称：三生国健 公告编号：2025-063 三生国健药业（上海）股份有限公司 关于收到实际控制人《解除<一致行动协议>的通知 函》的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本事项系三生国健药业（上海）股份有限公司（以下简称"公 司"）的实际控制人 LOU JING 解除与 TAN BO、苏冬梅、黄斌签署的 《一致行动协议》。 本次解除一致行动关系不会导致公司控股股东、实际控制人发 生变化，亦不会影响公司治理结构和持续经营。 公司于近日收到公司实际控制人 LOU JING 先生出具的《解除< 一致行动协议>的通知函》，现将有关情况公告如下： 一、原《一致行动协议》签署情况 根据 LOU JING 与 TAN BO、苏冬梅、黄斌签署的《一致行动协议》， 各方确认，自三生制药在香港联交所上市之日起，TAN BO、苏冬梅、 黄斌及其间接持有或控制的实体在三生制药董事会及股东大会审议 相关事项时，均与 LOU JING 在事实上保持了一致意见及一致行动， 并承诺协议签 ...

Core Viewpoint - The hair loss treatment market in China is rapidly growing, with over 339 million people affected, and a significant portion of this demographic being under 35 years old. The market is projected to reach a valuation of hundreds of billions [1]. Group 1: Company Overview - Mandi International, a subsidiary of 3SBio, has submitted an application for an IPO on the Hong Kong Stock Exchange, focusing on its minoxidil product line for hair loss treatment [1]. - The company was founded in 2001 and launched China's first 5% minoxidil solution, filling a gap in the market for effective hair loss treatments [2]. - Mandi's second-generation product, a 5% minoxidil foam, became a bestseller, selling over 2.5 million bottles in its first year and generating over 300 million yuan in revenue [2]. Group 2: Financial Performance - Mandi International's revenue grew from 982 million yuan in 2022 to 1.455 billion yuan in 2024, with a compound annual growth rate of 21.7%. Net profit increased from 202 million yuan to 390 million yuan during the same period [2]. - The gross profit margin remained above 80% over three years, reaching 82.7% in 2024, which is significantly higher than many pharmaceutical companies [2]. - Sales expenses rose from 476 million yuan in 2022 to 375 million yuan in the first half of 2025, exceeding 50% of revenue due to business expansion and marketing activities [3]. Group 3: Research and Development - R&D expenses increased significantly in 2024 to 92.2 million yuan but dropped to 19.5 million yuan in the first half of 2025, primarily due to the absence of certain costs incurred in the previous year [3]. Group 4: Leadership and Strategy - The company is led by Lou Jing, a second-generation pharmaceutical executive, who has a history of successful IPOs and acquisitions in the pharmaceutical sector [4][5]. - Mandi International is also expanding into the weight management market, with plans to submit a drug registration application for a semaglutide injection in 2026 [6]. - The company aims to use the funds from its IPO to enhance R&D capabilities, expand product offerings, and strengthen marketing and operational efficiency [7].

Core Insights - The global biopharmaceutical innovation landscape, traditionally dominated by multinational corporations, is undergoing significant structural changes, with China's innovative drug industry emerging as a key player on the global stage [1] - China's transition from a "fast follower" to an "originator" in innovative drugs is becoming an irreversible trend, as highlighted by international media [1] - Data shows a notable increase in China's share of global clinical trials and licensing transactions, with Chinese biotech companies outperforming their U.S. counterparts in stock price growth over the past year [1][3] Group 1: Market Dynamics - Multinational corporations are increasingly inclined to source early-stage innovative pipelines from China due to cost-effectiveness, with costs in China being 30%-40% lower than in the U.S. [2] - The collaboration between domestic companies and multinationals is exemplified by the $12.5 billion upfront payment from Pfizer to 3SBio for overseas rights to a bispecific antibody, marking a record for domestic innovative drugs [2][3] - The Chinese innovative drug sector is expected to see a surge in licensing transactions, with projections indicating that total licensing amounts could exceed $100 billion in the first three quarters of 2025 [3] Group 2: Investment Trends - The biopharmaceutical sector is experiencing a business development (BD) boom, with significant transactions such as the $12 billion collaboration between Hengrui Medicine and GSK, indicating strong interest from multinational companies [3][4] - Investment institutions are focusing on the biopharmaceutical sector, with approximately 80% of the market value concentrated in biotechnology and pharmaceuticals, driving capital flow into these areas [5] - The market is witnessing a shift from "story-driven" investment decisions to a focus on the hard capabilities of companies, emphasizing the importance of clinical data and product quality [9][10] Group 3: Future Outlook - The innovative drug market is expected to thrive, with projections indicating that the Hang Seng Index could double by 2025, driven by favorable policies and a rebound in industry valuations [7] - The Chinese innovative drug sector is anticipated to recover strongly in 2025, with the overall revenue of listed companies in this sector reaching 48.83 billion yuan, a 22% year-on-year increase [7] - The market is seeing a resurgence in IPO activity, with over 20 companies currently queued for listing in Hong Kong, reflecting renewed investor interest in the biopharmaceutical sector [12][13]

Core Viewpoint - The article discusses the significant growth and strategic moves of the "San Sheng" group, particularly under the leadership of Liu Jing, who has successfully navigated the company through multiple key capital market transactions, including the planned IPO of Mandi International in Hong Kong. Company Overview - Liu Jing, the second-generation leader of the "San Sheng" group, is known for his adept capital operations since taking over in 2012 [1] - Under Liu's leadership, San Sheng Pharmaceutical transitioned to the Hong Kong Stock Exchange and successfully spun off San Sheng Guojian for independent listing in 2020 [1] Stock Performance - Both San Sheng Pharmaceutical and San Sheng Guojian have seen substantial stock price increases this year, with San Sheng Pharmaceutical's stock rising nearly fourfold [2] - Liu Jing's family wealth has also increased significantly, ranking 443rd on the Hurun Rich List with a net worth of 15 billion yuan [2] Upcoming IPO - In November 2023, San Sheng Pharmaceutical plans to spin off its subsidiary Mandi International for a Hong Kong IPO, marking the third capital market platform for the "San Sheng" group [2] - Mandi International's core product, Minoxidil hair growth solution, holds a 57% market share in China's hair loss medication market, maintaining the top position for ten consecutive years [2] Valuation and Investment - Mandi International has a post-investment valuation of 5.8 billion HKD following a Series A funding round that raised approximately 50 million USD [5] - The company has received investments from notable entities, including Alibaba Health [3][5] Financial Performance - Mandi International's revenue has shown steady growth, with figures of 982 million yuan, 1.23 billion yuan, 1.45 billion yuan, and 743 million yuan for the years 2022 to 2025 [11] - The flagship product series, Mandi®, has contributed approximately 90% of the company's revenue during the reporting period [12] Dividend Policy - Mandi International has implemented a "clearance-style dividend" policy, distributing a total of 1.42 billion yuan in dividends over the reporting period, exceeding the total net profit [14] Cost Structure - The company maintains a high gross margin, with rates of 80.3%, 82%, 82.7%, and 81.1% during the reporting period, while net profit margins have fluctuated [13] - Sales expenses have been significantly higher than R&D expenses, with sales costs being nine times that of R&D [15][16] Distribution Network - Mandi International's revenue primarily comes from sales through third-party distributors, with a decreasing number of distributors from 173 to 106 over the reporting period [18]

Core Viewpoint - The report from Guojin Securities highlights that Sanofi's deep investment in the self-immune sector is expected to provide stable income from existing products in the short term [1] Group 1: Company Overview - Sanofi has been focused on the self-immune sector for over 20 years and has launched three products that are anticipated to ensure stable revenue and profit contributions in the near term [1] - The company has a pipeline of 26-28 products expected to enter commercialization in the coming years, leveraging its existing sales team and departmental experience to support the commercialization of new products [1] Group 2: Market Potential - The early-stage pipeline in the self-immune sector is considered high-quality and is expected to become a new generation of potential targets for growth [1] - Based on the DCF valuation model, the calculated reasonable market value for the company is 47.9 billion, corresponding to a target price of 77.56 yuan, with an initial coverage rating of "Buy" [1]

Core Insights - The biopharmaceutical sector is one of the fastest-growing areas in the pharmaceutical industry, driven by an aging population and increased public health awareness [1][5] - China's biopharmaceutical market is projected to grow from CNY 312 billion in 2019 to CNY 587.1 billion in 2024, and is expected to reach CNY 675.2 billion by 2025, with a potential to hit CNY 1.149 trillion in the next five years [1][5][6] - Innovation remains the core driver of growth in the biopharmaceutical industry, which is capital-intensive and requires significant R&D investment [1][6] Industry Definition and Classification - Biopharmaceuticals are medical products manufactured using biological methods, aimed at replicating the activity of natural substances [2][4] - They can be categorized into vaccines, blood products, biopharmaceutical drugs, diagnostic reagents, and others, with further subdivisions based on source or mechanism of action [2] Current Industry Status - The global biopharmaceutical market is expected to grow from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, with the original biopharmaceutical market projected to increase from USD 268.9 billion to USD 427.9 billion in the same period [5] - China plays a significant role in the global biopharmaceutical market, with rapid growth driven by favorable policies, increased R&D investment, and advancements in biotechnology [5][6] Industry Development Environment - Policies - The Chinese government has implemented various laws and policies to encourage biopharmaceutical R&D, including the Drug Registration Management Measures and regulations for clinical research and application of biomedical technologies [7] Competitive Landscape - The biopharmaceutical sector is recognized as a "new frontier" in the pharmaceutical industry, with major global players actively entering the market [9] - Key companies in China's biopharmaceutical industry include WuXi AppTec, Hengrui Medicine, ZhiFei Biological, BeiGene, and others, with a competitive landscape characterized by differentiated strategies [9] Future Development Trends - Market demand for biopharmaceuticals is expected to continue growing, supported by policy backing, technological advancements, and increased health awareness [10] - Domestic companies are transitioning from biosimilars to First-in-Class drugs, with examples like Hengrui Medicine's ADC drug showing superior efficacy [10][11] - Personalized medicine based on genetic testing is anticipated to become a trend, with increasing international recognition of Chinese innovative drugs [11]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 1.116 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 18.80%, primarily driven by increased licensing income from a collaboration project with Shenyang Sansheng and growth in its CDMO business [1] - The net profit attributable to shareholders for the same period was 399 million yuan, a significant increase of 71.15% compared to the previous year [1] - The company received a substantial upfront licensing payment from Pfizer, which contributed to a notable increase in net cash flow from operating activities and total assets compared to the previous year [2] Summary by Sections Financial Performance - Revenue for 2025 is projected to be 4.015 billion yuan, with a year-on-year growth of 236.4% [11] - Net profit for 2025 is expected to reach 2.854 billion yuan, reflecting a year-on-year increase of 305.0% [11] - The company maintained a healthy R&D expense ratio, with total R&D investments amounting to 368 million yuan, a year-on-year increase of 3.87% [1] Innovation Pipeline - The company is actively advancing its innovative pipeline, with several monoclonal antibody projects in various stages of clinical trials, including: 1. Anti-IL-17A monoclonal antibody ("608") for moderate to severe plaque psoriasis, with NDA application accepted [3] 2. Anti-IL-5 monoclonal antibody ("610") for severe eosinophilic asthma, currently in Phase III trials [3] 3. Anti-IL-4Rα monoclonal antibody ("611") for multiple indications, with several Phase III trials ongoing [3][4] 4. Anti-IL-1β monoclonal antibody ("613") for acute gouty arthritis, NDA application submitted and accepted [4] 5. Anti-BDCA2 monoclonal antibody ("626") for systemic lupus erythematosus, currently in Phase Ib/II trials [4] 6. Anti-TLIA monoclonal antibody ("627") for ulcerative colitis, in Phase I trials [8] Investment Recommendations - The company is expected to see significant growth in innovative product launches, maintaining previous profit forecasts with projected revenues of 4.015 billion yuan in 2025, 2.243 billion yuan in 2026, and 2.633 billion yuan in 2027 [9] - The earnings per share (EPS) for 2025 is projected to be 4.63 yuan, with a corresponding price-to-earnings (PE) ratio of 14 [11]

Market Overview - The biopharmaceutical sector experienced a decline of 0.52% on November 27, with Sangfor Biopharma leading the drop [1] - The Shanghai Composite Index closed at 3875.26, up 0.29%, while the Shenzhen Component Index closed at 12875.19, down 0.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Olin Biotech (688319) with a closing price of 25.49, up 4.98% and a trading volume of 103,300 shares, totaling 263 million yuan [1] - Rongchang Biopharma (688331) closed at 96.00, up 4.07% with a trading volume of 65,600 shares, totaling 623 million yuan [1] - Hualan Biological (301207) closed at 24.70, up 2.57% with a trading volume of 222,400 shares, totaling 538 million yuan [1] - Conversely, significant decliners included: - Sangfor Biopharma (688336) closed at 64.70, down 5.40% with a trading volume of 60,400 shares, totaling 400 million yuan [2] - Jindike (688670) closed at 29.32, down 5.11% with a trading volume of 155,900 shares, totaling 453 million yuan [2] - WanTai Biotech (603392) closed at 49.09, down 2.89% with a trading volume of 52,600 shares, totaling 260 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 251 million yuan from institutional investors, while retail investors experienced a net inflow of 229 million yuan [2] - Notable capital flows included: - Rongchang Biopharma had a net inflow of 64.13 million yuan from institutional investors, while retail investors saw a net outflow of 39.11 million yuan [3] - Olin Biotech experienced a net inflow of 7.37 million yuan from institutional investors, with retail investors facing a net outflow of 24.86 million yuan [3]

截至发稿，楼慧源累计任职时间7年79天，现任基金资产总规模43.33亿元，任职期间最佳基金回报 143.65%， 任职期间最差基金回报-21.86%。 数据显示，交银施罗德基金旗下1只基金重仓三生国健。交银医药创新股票A（004075）三季度增持 21.03万股，持有股数179.45万股，占基金净值比例为3.74%，位居第八大重仓股。根据测算，今日浮亏 损失约619.12万元。 交银医药创新股票A（004075）成立日期2017年3月23日，最新规模26.51亿。今年以来收益32.13%，同 类排名1165/4206；近一年收益29.31%，同类排名1461/4006；成立以来收益183.1%。 交银医药创新股票A（004075）基金经理为楼慧源。 11月27日，三生国健跌5.04%，截至发稿，报64.94元/股，成交3.50亿元，换手率0.85%，总市值400.54 亿元。 资料显示，三生国健药业(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路399号，成立日期 2002年1月25日，上市日期2020年7月22日，公司主营业务涉及抗体药物的研发、生产及销售业务。主营 业务收入构成为：销售商品75.2 ...